New joint Nordic tendering procedures published
Norway, Iceland and Denmark are publishing a number of new joint Nordic tendering procedures, this time with the environment as one of three important criteria.
In April 2019 Denmark, Norway and Iceland published the first joint Nordic tendering procedures. At that time, we only evaluated tenders on price.
This time, price and security of supply are important criteria in our evaluation of which suppliers will be awarded the contract. Furthermore, a new third criterion is the environment.
Supply-critical medicines
The joint Nordic tendering procedures include medicines in what we refer to as phases 5 and 6 of the medicine lifecycle. These are medicines that are potentially supply-critical or for which there is a de facto monopoly.
Specifically, the tendering procedures include the following medicines:
- Ampicillin
- Anagrelide
- Ceftazidime
- Ceftriaxone
- Cefuroxime
- Ciprofloxacin
- Gentamicin
- Meropenem
- Methotrexate
- Metronidazole
- Ondansetrone
- Paracetamol
- Vancomycin
The procurement period for the tendering procedures will run from 1 April 2022 to 1 March 2024, with option for extension.
Read more: We invite suppliers to dialogue on joint Nordic tendering procedures